 |
J&J prostate cancer drug improves survivalJohnson & Johnson's prostate cancer drug Zytiga improved survival in patients who had not received chemotherapy in a late-stage study, the company said on Thursday. An independent data monitoring committee unanimously recommended More… |
Tuesday 5 November 2024
